AdaptHealth (NASDAQ:AHCO) Stock Price Expected to Rise, Robert W. Baird Analyst Says

AdaptHealth (NASDAQ:AHCO) had its target price upped by Robert W. Baird from $14.00 to $16.00 in a research note released on Thursday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Other research analysts also recently issued reports about the company. Royal Bank of Canada lifted their target price on AdaptHealth from $11.00 to $14.00 and gave the company an “outperform” rating in a research note on Wednesday. UBS Group lowered their target price on AdaptHealth from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Canaccord Genuity Group lifted their target price on AdaptHealth from $13.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Truist Financial lifted their target price on AdaptHealth from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, AdaptHealth has a consensus rating of “Buy” and an average target price of $13.80.

AdaptHealth Trading Down 0.1 %

NASDAQ:AHCO opened at $11.09 on Thursday. The stock’s 50 day moving average price is $9.89 and its 200 day moving average price is $10.22. The company has a market capitalization of $1.49 billion, a PE ratio of -6.72, a P/E/G ratio of 1.08 and a beta of 1.12. The company has a quick ratio of 1.00, a current ratio of 1.24 and a debt-to-equity ratio of 1.34. AdaptHealth has a 52-week low of $8.35 and a 52-week high of $11.90.

Institutional Trading of AdaptHealth

Hedge funds have recently modified their holdings of the business. Intech Investment Management LLC lifted its holdings in shares of AdaptHealth by 223.2% in the 3rd quarter. Intech Investment Management LLC now owns 59,650 shares of the company’s stock valued at $670,000 after buying an additional 41,196 shares during the period. Victory Capital Management Inc. lifted its holdings in shares of AdaptHealth by 727.4% in the 3rd quarter. Victory Capital Management Inc. now owns 141,507 shares of the company’s stock valued at $1,589,000 after buying an additional 124,404 shares during the period. Royce & Associates LP lifted its holdings in shares of AdaptHealth by 13.5% in the 3rd quarter. Royce & Associates LP now owns 777,405 shares of the company’s stock valued at $8,730,000 after buying an additional 92,740 shares during the period. Barclays PLC lifted its holdings in shares of AdaptHealth by 361.3% in the 3rd quarter. Barclays PLC now owns 181,240 shares of the company’s stock valued at $2,034,000 after buying an additional 141,949 shares during the period. Finally, Principal Financial Group Inc. lifted its holdings in shares of AdaptHealth by 39.7% in the 3rd quarter. Principal Financial Group Inc. now owns 543,744 shares of the company’s stock valued at $6,106,000 after buying an additional 154,434 shares during the period. 82.67% of the stock is owned by institutional investors and hedge funds.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.